BACKGROUND: @entity9 is difficult to treat, and the available options are often inadequate. The expectorant @entity5923 also acts as a strong local anaesthetic and blocks @entity1372 channels about 40 times more potently than @entity3303 . It preferentially inhibits the channel subtype @entity8603 , which is expressed especially in nociceptive C-fibres. In view of the low @entity137 of @entity5923 , it seemed reasonable to try using it for the treatment of @entity9 that failed to respond to other standard options. MATERIAL AND METHODS: The medical records of seven @entity1 with severe @entity9 and @entity158 reduction following topical @entity5923 treatment are reported retrospectively. As standard therapies had not proved sufficient, a topical @entity5923 20   % cream was repeatedly applied by the @entity1 in the area of @entity9 . RESULTS: The reasons for @entity9 were @entity14000 (2   *), @entity4216 , @entity158 , @entity158 , @entity86 and foot @entity16 of unknown origin. The individual mean @entity158 intensity reported was between 4 and 6/10 (NRS), maximum @entity158 at 6-10/10 (NRS). The @entity158 reduction achieved individually following @entity5923 cream was 2-8 points (NRS) within 5-30  min and lasted for 3-8  h. @entity158 attacks were reduced in all five @entity1 presenting with this problem. Four @entity1 with no improvement after @entity3303 5   % and one @entity1 with no response to @entity2951 8   % nevertheless experienced a @entity158 reduction with topical @entity5923 . No @entity1 reported any side effects or skin changes during a treatment that has since been continued for up to 4 years. CONCLUSION: @entity5923 acts as a strong local anaesthetic and preferentially inhibits the nociceptively relevant @entity1372 channel subtype @entity8603 . For the first time, we report below on a relevant @entity158 relief following topical @entity5923 20   % cream in @entity1 with @entity9 . In view of the positive side effect profile, the clinical benefit in @entity1 with @entity158 should be investigated further.

Topical XXXX for the treatment of @entity9 : An initial clinical observation. English version.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity2951 :: ('MESH:D002211', 'Chemical') :: ['capsaicin'] @entity8603 :: ('6336', 'Gene') :: ['Nav 1.8'] @entity16 :: ('MESH:D009422', 'Disease') :: ['neuropathy'] @entity1372 :: ('MESH:D012964', 'Chemical') :: ['sodium'] @entity3303 :: ('MESH:D008012', 'Chemical') :: ['lidocaine'] @entity86 :: ('MESH:D019106', 'Disease') :: ['postoperative neuralgia'] @entity158 :: ('MESH:D010146', 'Disease') :: ['phantom pain', 'deafferentation pain', 'Pain', 'pain'] @entity4216 :: ('MESH:D020422', 'Disease') :: ['mononeuropathy multiplex'] @entity14000 :: ('MESH:D051474', 'Disease') :: ['postherpetic neuralgia'] @entity9 :: ('MESH:D009437', 'Disease') :: ['neuropathic pain', 'Neuropathic pain'] @entity5923 :: ('MESH:D000551', 'Chemical') :: ['ambroxol', 'Ambroxol']
@entity5923 :: (MESH:D000551,Chemical) :: ['ambroxol']
